Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide-Reference-Cited by-同舟云学术

Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide

Published:2024-02-12 Issue:4 Volume:67 Page:2425-2437
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

AghaAmiri Solmaz¹^ORCID,Ghosh Sukhen C.¹,Hernandez Vargas Servando¹^ORCID,Halperin Daniel M.²,Azhdarinia Ali¹^ORCID

Affiliation:

1. The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, 1881 East Road, 3SCR6.4680, Houston, Texas 77054, United States

2. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States

Funder

John S. Dunn Foundation

American Association for Cancer Research

Neuroendocrine Tumor Research Foundation

Cancer Prevention and Research Institute of Texas

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00223

Reference78 articles.

1. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

2. Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned

3. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

4. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

5. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme;Journal of Medicinal Chemistry;2024-08-13